BTAI Overview

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is5.50 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioXcel Therapeutics Inc revenue for the last quarter amounts to 206.00K USD, increased 22.62

BioXcel Therapeutics Inc. EPS for the last quarter amounts to -0.54 USD, decreased -64.00

BioXcel Therapeutics Inc (BTAI) has 29 emplpoyees as of May 31 2026.

Today BTAI has the market capitalization of 36.13M USD.